• About
• Links
• Contact
• Sitemap
• 

Neuropathic Pain - Drug Pipeline Analysis and Market Forecasts to 2015

Summary

The report is an essential source of information and analysis on the global neuropathic pain market. The report identifies the key trends shaping and driving the global neuropathic pain market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global neuropathic pain sector.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by team of industry experts.

Scope

The scope of the report includes:

Annualized global neuropathic pain market revenues data from 2006 to 2008, forecast forward for 7 years to 2015.

Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action includes opioid receptor agonists, cannabinoid receptor modulators, NMDA antagonists, protein kinase inhibitors, ion channel targetters, serotonin norepinephrine reuptake inhibitors, adenosine agonists, cytokine modulators, AMPA antagonists, nicotinic receptor agonists, TRPV1 receptor agonists, selective subtype sodium channel antagonists, iNOS/nNOS dual inhibitors.

Analysis of the current and future market competition in the global neuropathic pain market. Key future market players covered are NeurogesX, Cephalon Inc., UCB S.A., Newron Pharmaceuticals, EpiCept Corporation, GW Pharmaceuticals, Johnson & Johnson, Avanir pharmaceuticals, GlaxoSmithKline plc., AstraZeneca.

Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with neuropathic pain.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the global neuropathic pain market.

Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global neuropathic pain market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

What’s the next big thing in the global neuropathic pain market landscape? – Identify, understand and capitalize.

Table of Contents

1 Table of contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Global Neuropathic Pain Market: Market Characterization

• 2.1 Overview
• 2.2 Neuropathic Pain Market Size
• 2.3 Neuropathic Pain Market Forecast and CAGR
• 2.4 Drivers and Barriers for Neuropathic Pain Market
  • 2.4.1 Drivers for Neuropathic Pain Market
  • 2.4.2 Barriers for Neuropathic Pain Market
• 2.5 Opportunity and Unmet Need
• 2.6 Key Takeaway

3 Global Neuropathic Pain Market: Competitive Assessment

• 3.1 Overview
• 3.2 Strategic Competitor Assessment
• 3.3 Product Profile for the Major Marketed Products in the Neuropathic Pain Market
  • 3.3.1 Lyrica (pregabalin)
  • 3.3.2 Cymbalta (duloxetine)
  • 3.3.3 Lidoderm (lidocaine patch 5%)
  • 3.3.4 Neurontin (gabapentin)
• 3.4 Key Takeaway

4 Global Neuropathic Pain Market: Pipeline Assessment

• 4.1 Overview
• 4.2 Strategic Pipeline Assessment
  • 4.2.1 Technology Trends Analytic Framework
• 4.3 Neuropathic Pain Therapeutics – Promising Drugs under Clinical Development
• 4.4 Molecule Profile for Promising Drugs under Clinical Development
  • 4.4.1 Vimpat (lacosamide)
  • 4.4.2 Qutenza (capsaicin 8%)
  • 4.4.3 Fentora
  • 4.4.4 Ralfinamide
  • 4.4.5 NP-1
  • 4.4.6 Sativex
• 4.5 Neuropathic Pain Therapeutics Market – Clinical Pipeline by Mechanism of Action
• 4.6 Neuropathic Pain Pipeline – Pipeline by Clinical Phases of Development
  • 4.6.1 Neuropathic Pain Therapeutics – Regulatory Filing and Phase III Clinical Pipeline
  • 4.6.2 Neuropathic Pain Therapeutics – Phase II Clinical Pipeline
  • 4.6.3 Neuropathic Pain Therapeutics – Phase I Clinical Pipeline
  • 4.6.4 Neuropathic Pain Therapeutics – Preclinical Pipeline
  • 4.6.5 Neuropathic Pain Therapeutics – Discovery Pipeline
• 4.7 Discontinued / Suspended Drugs for Neuropathic Pain
• 4.8 Key Takeaway

5 Global Neuropathic Pain Market: Implications for Future Market Competition

6 Global Neuropathic Pain Market: Future Players in Neuropathic Pain Market

• 6.1 Introduction
• 6.2 NeurogesX
  • 6.2.1 Overview
  • 6.2.2 Pain Portfolio
  • 6.2.3 Neuropathic Pain Product Portfolio
• 6.3 Cephalon Inc.
  • 6.3.1 Overview
  • 6.3.2 Pain Portfolio
  • 6.3.3 Neuropathic Pain Product Portfolio
• 6.4 UCB S.A.
  • 6.4.1 Overview
  • 6.4.2 Pain Portfolio
  • 6.4.3 Neuropathic Pain Portfolio
• 6.5 Newron Pharmaceuticals
  • 6.5.1 Overview
  • 6.5.2 Pain Portfolio
  • 6.5.3 Neuropathic Pain Product Portfolio
• 6.6 EpiCept Corporation
  • 6.6.1 Overview
  • 6.6.2 Pain Portfolio
  • 6.6.3 Neuropathic Pain Product Portfolio
• 6.7 GW Pharmaceuticals
  • 6.7.1 Overview
  • 6.7.2 Pain Portfolio
  • 6.7.3 Neuropathic Pain Product Portfolio
• 6.8 Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  • 6.8.1 Overview
  • 6.8.2 Pain Portfolio
  • 6.8.3 Neuropathic Pain Product Portfolio
• 6.9 Avanir Pharmaceuticals
  • 6.9.1 Overview
  • 6.9.2 Pain Portfolio
  • 6.9.3 Neuropathic Pain Product Portfolio
• 6.10 GlaxoSmithKline Plc.
  • 6.10.1 Overview
  • 6.10.2 Pain Portfolio
  • 6.10.3 Neuropathic Pain Product Portfolio
• 6.11 AstraZeneca
  • 6.11.1 Overview
  • 6.11.2 Pain Portfolio
  • 6.11.3 Neuropathic Pain Product Portfolio

7 Global Neuropathic Pain Market: Appendix

• 7.1 Definitions
• 7.2 Acronyms
• 7.3 Research Methodology
  • 7.3.1 Coverage
  • 7.3.2 Secondary Research
  • 7.3.3 Forecasting
  • 7.3.4 Primary Research
  • 7.3.5 Expert Panel Validation
• 7.4 Contact Us
• 7.5 Disclaimer
• 7.6 Sources

1.1 List of Tables

• Table 1: Global Neuropathic Pain Therapeutics Market, Revenue Forecasts ($m), 2006–2015
• Table 2: Major Marketed Products Comparison in the Neuropathic Pain Market, 2009
• Table 3: Neuropathic Pain Therapeutics – Most Promising Drugs under Clinical Development, 2009
• Table 4: Neuropathic Pain Therapeutics – Regulatory Filing and Phase III Clinical Pipeline, 2009
• Table 5: Neuropathic Pain Therapeutics – Phase II Clinical Pipeline, 2009
• Table 6: Neuropathic Pain Therapeutics – Phase I Clinical Pipeline, 2009
• Table 7: Neuropathic Pain Therapeutics – Preclinical Pipeline, 2009
• Table 8: Neuropathic Pain Therapeutics – Discovery Pipeline , 2009
• Table 9: List of Discontinued Drugs for Neuropathic Pain, 2009
• Table 10: NeurogesX – Pain Marketed Products, 2009
• Table 11: NeurogesX – Pain Pipeline Products, 2009
• Table 12: Cephalon Inc. – Pain Marketed Products, 2009
• Table 13: Cephalon Inc. – Pain Pipeline Products, 2009
• Table 14: UCB S.A. – Pain Pipeline Products, 2009
• Table 15: Newron Pharmaceuticals – Pain Pipeline Products, 2009
• Table 16: EpiCept Corporation – Pain Pipeline Products, 2009
• Table 17: GW Pharmaceuticals – Pain Marketed Products, 2009
• Table 18: GW Pharmaceuticals – Pain Pipeline Products, 2009
• Table 19: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. – Pain Marketed Products, 2009
• Table 20: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. – Pain Pipeline Products, 2009
• Table 21: Avanir Pharmaceuticals – Pain Pipeline Products, 2009
• Table 22: GlaxoSmithKline plc. – Pain Pipeline Products, 2009
• Table 23: AstraZeneca – Pain Pipeline Products, 2009

1.2 List of Figures

• Figure 1: Global Neuropathic Pain Market Forecast 2006–2015
• Figure 2: Opportunity and Unmet Need in the Neuropathic Pain Market, 2009
• Figure 3: Strategic Competitor Assessment of the Major Marketed Products in Neuropathic Pain, 2009
• Figure 4: Technology Trends Analytic Framework of the Neuropathic Pain Pipeline, 2009
• Figure 5: Technology Trends Analytic Framework of the Neuropathic Pain Pipeline – Description, 2009
• Figure 6: Neuropathic Pain Therapeutics Market – Clinical Pipeline by Mechanism of Action, 2009
• Figure 7: Neuropathic Pain Pipeline by Phase of Clinical Development, 2009
• Figure 8: Implications for Future Market Competition in the Neuropathic Pain Market, 2009
• Figure 9: Neuropathic Pain Therapeutics Market – Clinical Pipeline by Company, 2009
• Figure 10: Methodology
• Figure 11: Market Forecasting Model

Other users found this report page using the following search terms: neuropathic pain pain neuropathic market neuropathicpainmarketsize pipeline drug johnson drugs size development

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.

Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.